Quest Diagnostics Incorporated (NYSE:DGX) went up by 0.93% from its latest closing price compared to the recent 1-year high of $134.71. The company’s stock price has collected 1.97% of gains in the last five trading sessions. Press Release reported on 03/15/21 that Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test
Is It Worth Investing in Quest Diagnostics Incorporated (NYSE :DGX) Right Now?
Quest Diagnostics Incorporated (NYSE:DGX) scored a price-to-earnings ratio above its average ratio, recording 11.89 x from its present earnings ratio. Plus, the 36-month beta value for DGX is at 1.02. Opinions of the stock are interesting as 10 analysts out of 19 who provided ratings for Quest Diagnostics Incorporated declared the stock was a “buy,” while 0 rated the stock as “overweight,” 9 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $140.38, which is $15.41 above the current price. DGX currently public float of 131.67M and currently shorts hold a 2.55% ratio of that float. Today, the average trading volume of DGX was 1.37M shares.
DGX’s Market Performance
DGX stocks went up by 1.97% for the week, with a monthly jump of 1.98% and a quarterly performance of -0.19%, while its annual performance rate touched 60.42%. The volatility ratio for the week stands at 1.93% while the volatility levels for the past 30 days are set at 2.82% for Quest Diagnostics Incorporated. The simple moving average for the period of the last 20 days is 4.48% for DGX stocks with a simple moving average of 3.62% for the last 200 days.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Robert W. Baird repeating the rating for DGX by listing it as a “Neutral.” The predicted price for DGX in the upcoming period, according to Robert W. Baird is $137 based on the research report published on March 12th of the current year 2021.
KeyBanc Capital Markets gave a rating of “Overweight” to DGX, setting the target price at $144 in the report published on July 29th of the previous year.
DGX Trading at 1.41% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.76% of loss for the given period.
Volatility was left at 2.82%, however, over the last 30 days, the volatility rate increased by 1.93%, as shares surge +1.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.07% upper at present.
During the last 5 trading sessions, DGX rose by +1.97%, which changed the moving average for the period of 200-days by +1.35% in comparison to the 20-day moving average, which settled at $119.06. In addition, Quest Diagnostics Incorporated saw 4.27% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at DGX starting from PREVOZNIK MICHAEL E, who sale 5,574 shares at the price of $120.47 back on Mar 10. After this action, PREVOZNIK MICHAEL E now owns 40,152 shares of Quest Diagnostics Incorporated, valued at $671,500 using the latest closing price.
PREVOZNIK MICHAEL E, the SVP & General Counsel of Quest Diagnostics Incorporated, sale 801 shares at $115.49 during a trade that took place back on Feb 25, which means that PREVOZNIK MICHAEL E is holding 40,152 shares at $92,507 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- +22.31 for the present operating margin
- +38.30 for the gross margin
The net margin for Quest Diagnostics Incorporated stands at +15.10. The total capital return value is set at 18.40, while invested capital returns managed to touch 13.39. Equity return is now at value 23.10, with 10.70 for asset returns.
Based on Quest Diagnostics Incorporated (DGX), the company’s capital structure generated 71.13 points at debt to equity in total, while total debt to capital is 41.57. Total debt to assets is 34.28, with long-term debt to equity ratio resting at 66.76. Finally, the long-term debt to capital ratio is 39.01.
When we switch over and look at the enterprise to sales, we see a ratio of 2.12, with the company’s debt to enterprise value settled at 0.24. The receivables turnover for the company is 7.30 and the total asset turnover is 0.70. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.